# Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

> **NCT06134232** · PHASE2 · RECRUITING · sponsor: **Dendreon** · enrollment: 400 (estimated)

## Conditions studied

- Metastatic Castration-Resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** Sipuleucel-T Injection

## Key facts

- **NCT ID:** NCT06134232
- **Lead sponsor:** Dendreon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-02
- **Primary completion:** 2031-12-31
- **Final completion:** 2032-06-30
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2025-08-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06134232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06134232, "Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06134232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*